Boston Scientific (BSX)
NYSE:BSX
Want to see BSX full AI Analyst Report?
BSX Stock Chart & Stats
$64.23
$4.44(4.82%)
At close: 4:00 PM EST
$64.23
$4.44(4.82%)
Day’s Range― - ―
52-Week Range$56.05 - $109.50
Previous CloseN/A
Volume5.49M
Average Volume (3M)14.17M
Market Cap
$84.50B
Enterprise Value$92.70B
Total Cash (Recent Filing)$2.04B
Total Debt (Recent Filing)$12.42B
Price to Earnings (P/E)17.4
Beta0.74
Next Earnings
Jul 29, 2026EPS Estimate
0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.96
Shares Outstanding1,486,355,200
10 Day Avg. Volume13,132,437
30 Day Avg. Volume14,174,107
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)5.82
Price to Sales (P/S)7.03
P/FCF Ratio38.59
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit6.69
Enterprise Value/Ebitda18.89
Forecast
1Y Price Target
$89.12Price Target Upside38.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering27
EPS Forecast (FY)3.38
Revenue Forecast (FY)$21.73B
Bulls Say, Bears Say
Bulls Say
Clinical Trial EvidenceCHAMPION-AF and HI-PEITHO results met primary goals and showed a safety advantage on bleeding and improved outcomes in pulmonary embolism, which can boost clinician confidence and support wider clinical use of the Watchman and Ekos products.
Electrophysiology Market AdoptionGrowing adoption of pulse field ablation technology and related products positions the company to capture above-market electrophysiology growth and expand procedural revenue.
Management Guidance And Market DevelopmentDetailed guidance and management's focus on market development and physician outreach increase the likelihood that positive trial evidence translates into sustained procedure volume growth.
Bears Say
Product Performance SlowdownSlowing trends in key product lines such as Farapulse and Watchman could reduce revenue momentum and keep the stock sensitive to downside revisions.
Reimbursement And Competitive UncertaintyUncertainty around reimbursement combined with competing trial data can create clinician confusion and prompt some providers to reduce procedures, weighing on adoption and growth.
Safety Signal ConcernsObserved higher ischemic stroke rates in some analyses and debate over the trial noninferiority margin may deter some physicians and limit device adoption.
Boston Scientific News
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $56.05 and its highest was $109.50 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $84.50B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Jul 29, 2026 which is in 84 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Apr 22, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.788 by $0.012.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.83.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,486,355,200 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.8 in its last earnings report, beating expectations of $0.788. Following the earnings report the stock price went up 8.989%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Boston Scientific Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.12 (38.75% Upside)
$89.12 (38.75% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 90%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 8.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.47%
12-Months-Change
Fundamentals
Return on Equity
15.40%
Trailing 12-Months
Asset Growth
10.49%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Company Deck
BSX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed picture: a strong Q1 with organic growth and EPS above guidance, meaningful product and regional momentum (notably in EP/PFA, WATCHMAN clinical data, Asia Pacific), and solid capital priorities (buyback, Penumbra deal). However, management lowered near-term guidance and flagged several material headwinds — weaker Urology, some EP share pressure, margin compression (gross margin down 100 bps) and operational disruptions (POLARx discontinuation and supply issues) — leading to a more cautious full-year outlook. The company emphasizes confidence in longer-term strategy and product pipeline while taking near-term actions to control costs and invest commercially.View all BSX earnings summariesBSX Revenue Breakdown
33.99% MedSurg
66.01% Cardiovascular
BSX Stock 12 Month Forecast
Average Price Target
$89.12
▲(38.75% Upside)
Technical Analysis
Abbott Laboratories
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Ownership Overview
0.16% Insiders
24.46% Mutual Funds
4.26% Other Institutional Investors
49.51% Public Companies and Individual Investors